CareDx (CDNA) shares were up over 30% in Thursday trading after the company said a final policy affirmed coverage across its transplant surveillance offerings in kidney, heart, and lung.
The firm reported earlier the finalization of the Medicare Local Coverage Determination process related to molecular testing for solid organ allograft rejection.
The final Local Coverage Determination is expected to take effect on Aug. 30, CareDx added.
Price: 39.01, Change: +9.26, Percent Change: +31.11
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments